Skip to main content

Developing novel therapeutics

Medicinal chemists, chemical biologists and biochemists are developing novel anti-cancer therapeutics.

Hands wearing blue medical gloves holding a bottle of medicine with a syringe.
Researchers are seeking novel cancer drugs with increased effectiveness and decreased side effects.

The Cancer Research at Bath network aims to design and optimise anti-cancer drugs to enhance their activity while keeping side effects low. They must consider the physical and chemical properties of the drug, optimised drug-target interactions, and administration.

Natural compounds as a resource for novel anti-cancer drugs

Many widely-used anti-cancer therapeutics originate from natural sources. One of the challenges is producing these therapeutics at a large scale. Research is focussing on new ways to create simpler and improved replacements for natural anti-cancer drugs.

You can hear more aboout capsaicin, the spicy chemical in chilli peppers, and its implication in the treatment of cancer in Pharmacast, a brand new podcast from University of Bath students, Siobhan and Shaun.

Research groups: Lorenzo Caggiano, Tim Woodman (Department of Life Sciences), and Simon Lewis (Department of Chemistry).

Designing novel targeted anti-cancer therapeutics

Peptide-based drug discovery allows for the development of new anti-cancer lead compounds. Using innovative chemical strategies, the drugs can be more powerful and selective. Studies in this area include:

  • Library-derived peptide-based antagonists that can inhibit cancer-relevant targets, led by Jody Mason (Department of Life Sciences)
  • Covalent peptide-based inhibitors of cancer targets, led by Scott Lovell (Department of Life Sciences)
  • Peptide-targeted agents for photodynamic therapy and drug delivery, led by Ian Eggleston (Department of Life Sciences).

Get in touch

If you have any queries about Cancer Research at Bath, please contact Ute Jungwirth (Chair).